ascentage.com (AAPGV): Rentabilitas operasi

AAPGV (Ascentage Pharma Group Ltd) - tandha merek perusahaan

Risks for Ascentage Pharma Group (AAPGV) depend on the efficacy of olverembatinib in leukemia therapy, which determines the operating margin on the GURU.Markets chart, where the current value is -220.00. Business development relies on large-scale R&D investments in apoptosis inhibitors. The brand's high authority among hematologists and global partnerships confirm the company's significant therapeutic potential in the fight against oncology.

AAPGV - Rasio bathi operasi ascentage.com ing rentang 25.01.2025 - 19.11.2026

Ringkesan rincian data analitis Ascentage Pharma Group (AAPGV)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:Ascentage Pharma Group Ltd
Produk dadi Ascentage

Operating margin determines the portion of revenue remaining after all production costs are paid, but before accounting for debt obligations and taxes, serving as an indicator of resource management efficiency. By analyzing the operating margin chart for Ascentage Pharma Group (AAPGV), an investor can assess the extent to which costs for developing anti-cancer and anti-aging drugs translate into actual profit, confirming the viability of the business model.

Analisis pesaing Ascentage Pharma Group

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|CTOR - Rentabilitas operasi|Rentabilitas kegiatan operasi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Rentabilitas operasi|FATE: Rasio bathi operasi|WHWK (Aadi Bioscience, Inc.) - Margin operasi|TCRX (TScan Therapeutics) - Rasio bathi operasi|Rentabilitas operasi Champions Oncology (CSBR)|Rentabilitas kegiatan operasi XBiotech USA|Rentabilitas operasi CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Rentabilitas dodolan operasi|RADX - Rentabilitas operasi|ARTV - Margin operasi|Adlai Nortye Ltd (ANL) - Rentabilitas operasi|Veru Pharma - Tingkat bathi operasi|Rentabilitas operasi Tempest Therapeutics Corp|Rentabilitas dodolan miturut bathi operasi XLO (Xilio Therapeutics, Inc.)|Margin operasi RENB|MURA (Mural Oncology) - Tingkat bathi operasi|Margin operasi KAPA (Kairos Pharma Ltd)|OKUR: Rentabilitas dodolan miturut bathi operasi|GDTC: Margin dodolan operasi|CRIS - Margin operasi|APLM: Margin operasi|Rentabilitas dodolan operasi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Margin operasi|Margin operasi Genprex Inc.|Margin operasi CLDI|Margin dodolan operasi Sunshine Biopharma, Inc. SBFM|Margin operasi XBIO (Xenetic Biosciences)|Tingkat bathi operasi SLRX|PPBT - Rentabilitas operasi|AONC (aoncology.com) - Rentabilitas dodolan miturut bathi operasi|BGNE: Margin operasi|Checkpoint Therapeutics Inc (CKPT) - Margin operasi|ELEV (Elevation Oncology Inc.) - Margin operasi|icadmed.com (ICAD) - Rentabilitas kegiatan operasi|Margin operasi IKNA|NTBL (Notable Labs) - Tingkat bathi operasi|Margin operasi VIRX (Viracta Therapeutics)|Rentabilitas kegiatan operasi MorphoSys AG (MOR)|NAYA Biosciences Corp - Margin operasi